Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion type Assertion NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_head.
- NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion description "[All patients, who were on the standard treatment protocol, were subsequently divided into two groups according to their genotype, group A (92): TM with no mitigating factor and group B (34): TM carrying one or more mitigating factors in the beta- and/or alpha-globin genes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_provenance.
- NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion evidence source_evidence_literature NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_provenance.
- NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion SIO_000772 16800840 NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_provenance.
- NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion wasDerivedFrom befree-2016 NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_provenance.
- NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_assertion wasGeneratedBy ECO_0000203 NP556563.RAJgfvlvSZg8u4Hc6vB26ufI6tEoxtJP-KFWYVT_aHNik130_provenance.